COMMUNIQUÉS West-GlobeNewswire

EssilorLuxottica: Succès du placement d'une émission obligataire de 2 milliards d'euros à 2,99 %

29/08/2024 - 19:46

NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMÉRIQUE, AU CANADA, EN AUSTRALIE, AU JAPON, EN AFRIQUE DU SUD OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE IL SERAIT ILLÉGAL DE LE [...]

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2024

29/08/2024 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2024

29/08/2024 - 18:00

Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) [...]

RAMSAY SANTE : Provisional annual results at the end of June 2024

29/08/2024 - 17:35

PRESS RELEASE Paris, 29 th August 2024 Provisional annual results at the end of June 2024 As a mission-driven company, Ramsay Santé, thanks to its employees and medical community, is committed to expanding its [...]

RAMSAY SANTE : résultats annuels provisoires à fin juin 2024

29/08/2024 - 17:35

COMMUNIQUÉ DE PRESSE Paris, le 29 août 2024 Résultats annuels provisoires à fin juin 2024 Entreprise à mission, Ramsay Santé, grâce à ses collaborateurs et sa communauté médicale, s’engage à poursuivre et accélérer dans [...]

iTeos annonce sa participation aux prochaines journées Investisseurs

29/08/2024 - 17:06

WATERTOWN, Massachusetts et GOSSELIES, Belgique, 29 août 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS) (« iTeos »), une société biopharmaceutique au stade clinique, pionnière dans la découverte et le [...]

Major shareholder announcement

29/08/2024 - 15:17

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]

Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

29/08/2024 - 15:17

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President [...]

Anaptys Announces Participation in September Investor Conferences

29/08/2024 - 15:15

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]

Biomerica Reports Fiscal 2024 Year End Results

29/08/2024 - 15:00

Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger Growth Significant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $ [...]

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label

29/08/2024 - 15:00

FDA Final Approval to Precision Dosing for GLOPERBA ® Label. We believe GLOPERBA ® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in [...]

Psychemedics Corporation Launches New Ketamine Hair Testing Service

29/08/2024 - 15:00

DALLAS, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, is proud to announce the launch of its new ketamine hair testing solution. This innovative testing [...]

The International Myeloma Foundation (IMF) Brings Back ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2024

29/08/2024 - 14:45

LOS ANGELES, Aug. 29, 2024 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma Foundation (IMF) is reviving and amplifying its highly successful #kNOwMyeloma [...]

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

29/08/2024 - 14:30

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

29/08/2024 - 14:30

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and [...]

Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations

29/08/2024 - 14:30

WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB ® in the journal Pathogens . [...]

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

29/08/2024 - 14:30

SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today [...]

Safety Shot Clinical Data Results Confirm Breakthrough in Dramatic Reduction of Morning-After Symptoms Associated with Excessive Drinking

29/08/2024 - 14:30

The Company Showed a Substantial Reduction in the Physical, Negative Characteristics that Accompany Heavy Drinking in its Recent Groundbreaking, Clinical Study JUPITER, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Safety [...]

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

29/08/2024 - 14:15

RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological [...]